Venetoclax-Targeted Therapy in t(11;14) AL Amyloidosis Patients after Frontline Daratumumab and Cybord: A Retrospective Analysis from the French Amyloidosis Network
Murielle Roussel(Centre Hospitalier Universitaire de Limoges), Arnaud Jaccard(Centre Hospitalier Universitaire de Limoges), Ornella Rizzo(Hôpital Dupuytren), Éstelle Desport(Centre Hospitalier Universitaire de Poitiers), Thomas Chalopin(Centre Hospitalier Universitaire de Tours), Frank Bridoux(Université de Poitiers), Kentin Queru(Centre Hospitalier Universitaire de Limoges), Olivier Decaux(Hôpital Pontchaillou), Michelle Pirotte(University of Liège)
Cited by 3
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
|Journal of Clinical Oncology|2012|965
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
|Kidney International|2021|809